TARA - NASDAQ

Protara Therapeutics, Inc.

TARA·NASDAQ

$4.34

+3.2%

HealthcareBiotechnology

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$167.48M

EPS-1.3400

P/E Ratio-3.97

Earnings Date07/30/2026

tara

Net Receivables

Last Annual Value

1.26M

3-Year CAGR

37%

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Protara Therapeutics, Inc. Competitors Analysis of Net Receivables

TARA · NASDAQ

Company	Net Receivables	CAGR 3Y	CAGR 5Y	CAGR 10Y
Protara Therapeutics, Inc. NASDAQ:TARA	1.26M	73.2%	14.7%	N/A
Assembly Biosciences, Inc. NASDAQ:ASMB	974.00K	182.9%	23.7%	N/A
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	1.50M	N/A	N/A	1.2%
Immuneering Corporation NASDAQ:IMRX	0.00	N/A	N/A	N/A
Pyxis Oncology, Inc. NASDAQ:PYXS	700.00K	221.8%	N/A	N/A
Prelude Therapeutics Incorporated NASDAQ:PRLD	0.00	N/A	N/A	N/A
Invivyd, Inc. NASDAQ:IVVD	13.92M	146.2%	127.4%	N/A
Orchestra BioMed Holdings, Inc. NASDAQ:OBIO	95.00K	-1.4%	-4.7%	N/A
Codexis, Inc. NASDAQ:CDXS	10.73M	-18.6%	-22.2%	6.1%
OmniAb, Inc. NASDAQ:OABI	7.39M	24.3%	-19.0%	N/A
Sangamo Therapeutics, Inc. NASDAQ:SGMO	10.51M	37.2%	10.6%	7.3%

Protara Therapeutics, Inc. Fair Value Envelope

TARA · NASDAQ

Our analysis suggests that TARA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.34, this represents a potential HIDDEN relative to our calculated worth for Protara Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $4.34

Related Guides

Blog Categories

Continue your TARA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.